DCGI Nod To Covovax For 12-17 Years Age Group
- India's drug regulator has granted restricted use of COVID-19 vaccine Covovax.
- Covavax will become the fourth vaccine for the age group of 12-17 years.
- DCGI approved covavax for adults last December.
New Delhi: India’s drug regulator has granted restricted emergency use authorisation to Serum Institute of India’s COVID-19 vaccine Covovax for the 12-17 years age group subject to certain conditions, official sources said on Wednesday. It is the fourth vaccine to receive the regulator’s nod for use among those below 18 years. The Drugs Controller General Of India’s (DCGI) approval comes after the Subject Expert Committee on COVID-19 of the CDSCO last week recommended granting emergency use authorisation (EUA) to Covovax for those aged 12 to 17.
The health ministry has consistently said that additional needs for vaccination and inclusion of population for vaccination are examined constantly. In the EUA application to DCGI, Prakash Kumar Singh, director (government and regulatory affairs) at SII on February 21st had stated that the data from two studies on about 2707 children aged 12 to 17 years show that Covovax is highly efficacious, immunogenic, safe and well-tolerated in this age group of children. “This approval will not only be beneficial for our country alone but will benefit the entire world, fulfilling our prime minister’s vision of ‘making in India for the world’.
The DCGI has already approved Covovax for restricted use in emergency situations in adults on December 28th. It has not yet been included in the country’s vaccination drive. Covovax is manufactured by technology transfer from Novavax and is approved by the European Medicines Agency for conditional marketing authorisation and also granted emergency use listing by WHO on December 2017, 2020. India has been using Bharat Biotech’s Covaxin to vaccinate adolescents between 15-18 years. ZyCov-D is the first vaccine cleared by India’s drug regulator for inoculation of those aged 12 years and above in August last year. Indigenously developed Covaxin received approval for emergency use in 12 to 18 in December last year.